Work

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

Year: 2012

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-012-9869-8

Authors: Kenneth J. Pienta, Jean-Pascal Machiels, Dirk Schrijvers, Boris Alekseev, Mikhail Shkolnik, Simon J. Crabb, Susan Li, Shobha Seetharam, Thomas A. Puchalski, Chris Takimoto, Yusri Elsayed, Fitzroy Dawkins, Johann S. de Bono

Institutions: University of Michigan, U-M Rogel Cancer Center, Cliniques Universitaires Saint-Luc, UCLouvain, KU Leuven, P.A. Hertzen Moscow Oncology Research Institute, Russian Scientific Center of Radiology and Surgical Technologies, University of Southampton, Janssen Research & Development (United States), Royal Marsden NHS Foundation Trust, Institute of Cancer Research

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2071959986

FWCI: 9.009

Cites: 26

Cited by: 412

Related to: 10